Home MarketCipla Ltd.

Cipla Ltd. Stock Info: As on 2018-04-19 15:59:19



52 Week Range
Day's Range526.14 - 643.06
Value Traded (in ₹ Cr.) 89.15



Change %
52 Week Range
Day's Range525.47 - 642.24
Value Traded (in ₹ Cr.) 2.81

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 177,682,187.00 22.07%
IndianPromoters 117,803,409.00 14.63%
Mutual Funds/UTI 73,308,763.00 9.11%
FII 185,580,848.00 23.06%
Employee 0.00 0.00%
Public 134,712,856.00 16.74%
Government 0.00 0.00%
Others 63,005,757.00 7.83%

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 3.40
Basic EPS (Rs.) 18.21
Cash EPS 23.71
BVPerShare Excl 149.19
Operating Revenue 150.83
PBDITPerShare 29.05
Dividend 2.00
NPPerShare 18.20
Current Ratio 2.19
Quick Ratio 1.20
PriceToBV 3.43
Earnings 0.03
PBDIT Margin 19.25
PBT Margin 14.39
NP Margin 12.06
Return On Assets 9.59
Retention Ratios 87.62
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 12,398.02
Total Expenses 10,654.05
EBITDA 2,333.73
PBT 1,743.97
PAT 1,462.30
Net Income 1,462.30
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 5,539.17
Total Expenses 5,211.62
EBITDA 101.16
PBT 283.57
PAT 300.60
Net Income 0.00
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 160.68
Net worth 11,985.88
Investments 4,255.78
Total Liability 15,239.05
Total debt 1,131.81
Net block 4,377.16
Total Assets 15,239.05
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 160.68
Net worth 12,339.29
Investments 4,856.81
Total Liability 16,019.46
Total debt 1,131.81
Net block 4,396.94
Total Assets 16,019.46
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

560.25 560 0.04

Abbott India Ltd.

6184.05 6171.75 0.2

Ajanta Pharma Ltd.

1385.2 1378.7 0.47

Albert David Ltd.

377.25 377 0.07

Alembic Ltd.

57.8 57.65 0.26

Alembic Pharmaceuticals Ltd.

500.7 499.05 0.33

Alkem Laboratories Ltd.

1797.5 1779.25 1.03
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

55.6 56.1 -0.89

Aarti Drugs Ltd.

562.6 559.95 0.47

Aayush Food & Herbs Ltd.

62 60.5 2.48

Abbott India Ltd.

6205.45 6182.15 0.38

ABL Bio-Technologies Ltd.

0.81 0.78 3.85

Addlife Pharma Ltd.

0.46 0 0

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 1,728.40
Cash from investing activities -1,205.67
Cash from financing activities -547.00
Net change in cash -24.58

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
ICICI Prudential Balanced Fund 1.84%
HDFC Prudence Fund - Regular Plan 0.99%
ICICI Prudential Focused Bluechip Equity Fund 2.08%
ICICI Prudential Balanced Advantage Fund 1.09%
HDFC Equity Fund - Regular Plan 1.36%
ICICI Prudential Dynamic Plan 1.98%

SBI Equity Savings Fund: change in investment factsheets for March

SBI Equity Savings Fund has announced change in investment factsheets and fund flash for the month ended March 31, 2018. As on Mar 31, 2018, the total size of the Fund was Rs 1,879.44 crores, compared with Rs 1,605.10 crores in the last month. The Fund's NAV per unit was Rs 12.59 for Growth, while 52-Week High and Low ranges were Rs 12.80 and Rs 11.57 respectively. The Equity - Hybrid fund with Growth plan was launched on May 11, 2015 and managed by Fund Managers Neeraj Kumar, Ruchit Mehta. The top five companies based on a percentage of total holdings were HDFC Bank Ltd. (62.99 Cr.), Housing Development Finance Corporation Ltd. (48.50 Cr.), ICICI Bank Ltd. (39.44 Cr.), Maruti Suzuki India Ltd. (38.47 Cr.) and Dewan Housing Finance Corporation Ltd. (36.12 Cr.). SBI Equity Savings Fund is promoted by SBI Mutual Fund and managed by SBI Funds Management Pvt. Ltd..

19-04-2018 11:20

VA TECH WABAG bags order from BUIDCO

VA TECH WABAG Limited ('WABAG'), a leading pure play water technology Indian Multinational has said that it has been awarded an order for INR 253 Crores by Bihar Urban Infrastructure Development Corporation Ltd ('BUIDCO'), under the prestigious Namami Gange scheme (National Mission for Clean Ganga NMCG). The scope includes survey, review, redesign and build new sewerage system along with a pumping station and operation and maintenance of 10 years at Karmalichak, Patna. The project will be jointly financed by World Bank and NMCG. Commenting on this development, Pankaj Sachdeva, CEO—India Cluster said, It is heartening to witness the steady flow of orders under Namami Gange. The project will help in meeting the sewage treatment needs to ensure that no untreated wastewater is discharged in the River Ganga from this zone. Meanwhile, shares of the company were trading at Rs 520.95 apiece up 1.97 per cent from the previous close at 11:03 hrs on BSE.

19-04-2018 11:01

UltraTech Cement commissions greenfield factory in MP

UltraTech Cement has said that it has commissioned a greenfield clinker capacity of 2.5 mtpa at Manawar, District-Dhar, Madhya Pradesh. The plant has been commissioned in record time of less than 365 days-setting a global benchmark for size of such capacity . Yet another benchmark is setting up the greenfield plant at less than $90/mt. The Kiln is designed for multi fuel and the entire system of using alternative fuels , which enhances the energy efficiency and reduces environmental impact, is an integral part of the plant. Along with the kiln, UltraTech has also commissioned a cement grinding facility of 1.75 mtpa capacity and an auto loading facility. This state-of-the-art manufacturing facility has been built with best in class safety standards . Another cement grinding facility of 1.75 mtpa capacity as well as a waste heat recovery system of 13 MW capacity is under erection and both are expected to be completed before September , 2018. Meanwhile, shares of the company were trading at Rs 4144.80 apiece up 3.69 per cent from the previous close at 11:04 hrs on BSE.

19-04-2018 11:00

Sanjay Kumar Moitra takes over as Director (Onshore), ONGC

Sanjay Kumar Moitra today took over as the new Director (Onshore) of Oil and Natural Gas Corporation (ONGC). As Director (Onshore), he will look after oil and gas production from ONGC's onshore fields, the company said in a statement. With over 35 years of experience in oil and gas production activities at various Indian basins, Moitra has conceptualised many out-of-box ideas for efficient resource management leading to implementation of a large number of complex and high-value projects in India's oil & gas industry, it said. Before assuming charge as Director (Onshore), he headed the Bassein & Satellite (B&S) Asset in Western Offshore, Mumbai - the highest gas-producing and second highest oil producing Asset of ONGC and the country - since 2013. The B&S Asset caters to about 30 per cent of total gas production of the country. A Mechnaical Engineer from Jabalpur University, Moitra joined ONGC in 1982. He also did an Advance Management Course from Cambridge University, UK in 2011.

19-04-2018 10:53

Airtel tops 4G download speed, Jio in coverage area: OpenSignal

Bharti Airtel has topped the chart of 4G service providers with 9.31 mbps download speed on its network, a report by broadband parameters research firm OpenSignal said. Idea Cellular and Vodafone followed Airtel with 7.27 mbps and 6.98 mbps download speed respectively while Jio network was found to be the slowest compared to the three operators with a download speed of 5.13 mbps, according to tests conducted by OpenSignal between December 2017 to February 2018. Airtel held onto our 3G and 4G speed awards since OpenSignal's last report, and it wrested our overall speed award away from Jio, locking down the top spot in all three of our speed categories. Jio, however, remained the closest contender in overall speed due to its high level of 4G access, OpenSignal report said. In overall speed, Airtel registered 6 mbps download speed while Jio recorded 5.1 mbps download speed. Idea, Vodafone and state-run BSNL followed Jio in terms of overall download speed. In overall speed test, OpenSignal considered download speed across 4G, 3G and 2G network of individual operators. Airtel also lead the chart for 3G downlaod speed with 2.73 mbps average top speed. The broadband speed measurement has become bone of contention in the industry as test conducted by the Telecom Regulatory Authority of India has found Reliance Jio as the fastest 4G services providers in several months. Jio, however, found top spot in terms of 4G network coverage, as per the report. Jio continued to dominate our 4G availability metric as our testers were able to access an LTE (4G) signal 96.4 per cent of the time, the report said. In 4G availability test OpenSignal measures how often users can access a 4G network rather than a measure of geographic or population coverage. Jio was followed by Vodafone in 4G coverage. While India is making big leaps forward in 4G availability, we can't say the same thing about 4G speed. There was very little change in our speed metrics since our last report. Our results show Airtel's 4G speeds ticked up incrementally, while the other three operators saw their speeds fall off slightly since our last report, OpenSignal said.

19-04-2018 10:50

Cipla - Shareholding for the Period Ended March 31, 2018

Cipla Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018.

18-Apr-2018 07:12 PM

Cipla - Statement Of Investor Complaints For The Quarter Ended March 2018

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
Name of the Signatory :- Mr. Rajendra Chopra
Designation :- Company Secretary and Compliance Officer

18-Apr-2018 06:45 PM

Cipla - News Verification

The Exchange has sought clarification from Cipla Limited with respect to recent news item captioned Cipla gains 4% after USFDA inspection with no data integrity or repeat observations. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Cipla Limited has submitted their response.

17-Apr-2018 11:05 AM

Cipla - News Clarification

Please find attached letter dated 16th April 2018

16-Apr-2018 07:09 PM

Cipla - News Verification

The Exchange has sought clarification from Cipla Limited with respect to recent news item captioned Cipla gains 4% after USFDA inspection with no data integrity or repeat observations. In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

16-Apr-2018 04:53 PM

Cipla - Shareholding for the Period Ended March 31, 2018

Cipla Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018.

18-Apr-2018 07:12 PM

Cipla - Statement Of Investor Complaints For The Quarter Ended March 2018

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
Name of the Signatory :- Mr. Rajendra Chopra
Designation :- Company Secretary and Compliance Officer

18-Apr-2018 06:45 PM

Cipla - News Clarification

Please find attached letter dated 16th April 2018

16-Apr-2018 07:09 PM

Corporate Details

About Management

1935 - The Company was Incorporated at Mumbai. 1979 - The Company acquired a plot of land from MIDC at Patalganga in Kulaba district of Maharashtra State about 55 kms. from Mumbai. - 18,773 Bonus equity shares issued in proportion 1:1. 1984 - The name of the Company was changed from The Chemical Industrial & Pharmaceutical Laboratories Ltd., to the present one with effect from 20th July. 1985 - 37,546 Bonus equity shares issued in proportion 1:1 in January 1986. 1986 - During August, the Company obtained the consent of the Controller of Capital Issues to issue 3,00,000-15% secured non-convertible redeemable debentures of Rs 100 each aggregating to Rs 300 lakhs by private placement. The entire issue was subscribed by public financial institutions. They are redeemable at a premium of 5% during 1993-94. 1987 - The Company launched several new products viz., Asthalin and Beclate Rotahalers/Rotacaps-dry powder inhalation devices for asthma, presolar capsules - the first synergistic combination of a beta blocker and a sustained release calcium channel blocker for hypertension, Restyl tablets - the first anxiolytic-cum-anti depressant, Theo-Asthalin SR tablets - the first sustained release combination of two widely used bronchodilators, bromolin dry syrup and bromolin-250 capsules - antibiotic-cum-mucolytic agents, dilgard tablets - a new calcium channel blocker for angina, ibugesic plus suspension - a non steroidal anti inflammatory and anti-pyretic analgesic for paediatric use. - 75,092 Bonus equity shares issued in proportion 1:1. 1989 - The latest drugs introduced during the year were (i) Ciplox tablets (250 & 500 mg.) and infusion (50 and 100 ml.), a broad spectrum fluoroquinolone antibacterial for severe infections, (ii) cefadur capsules (250 & 500 mg.) and syrup (30 ml.), a cephalosporin antibiotic, (iii) Ulcimax tablets (20 & 40 mg.), a long-acting H2 antogonist for peptic ulcers and (iv) theoped syrup, a paediatric bronchodilator. Sales in the Company's `PROTEC' division exceeded Rs 5.50 crores for the second year of its operations. 1990 - The Company launched several new products viz., Aerocort inhaler, an anti-inflammatory bronchodilator, Norflox eye/ear drops - a broad spectrum fluoroquinolone antibacterial, Pirox Gel - the first topical piroxicam formulation in the country, Cofenac tablets - an anti-infammatory analgesic, Kinetal 400 tablets - a multi-functional drug for vascular insufficiency, Novaclox Ped tablets - a dispensible combination antibiotics, Terfed tablets and Suspension - a new non-sedative antihistamine, Depryl tablets - a broad - spectrum antidepressant, Asthalin Respirator Solution - a bronchodilator for pressure ventilation in acute asthma. The Company spent Rs 4.22 crores on R&D and Rs 8.09 crores on modernisation and expansion of plant and machinery. 1991 - The new products launched during the year were lomac capsules - a new antiulcerant, cromal inhaler - the first optimum - dose inhalant prophylactic for asthma, ciplox eye drops - the total bactericide for ocular infections, etosid injection - the first injection of indigenously manufactured etoposide for cancer therapy, proflox tablets - a key fluoroquinolone antibiotic and vasopril tablets - an ACE inhibitor for long-term management of hypertension. The research and development win g of the Company developed during the y ar felodipine - the latest anti-hypertensive drug, selegilinje - a new bulk drug for the treatment of Parkinson's disease, cetirizine HCI - an anti-histamine drug and nimodipine - a cerebral vasodilator. Work on the anti-AIDS drug AZT reached an advance stage of development. The research and development wing also developed anthelmintics oxfendazole and oribendazole, two veterinary products for exports. - In May, 6,000 equity shares offered at par as rights to pref. shareholders in prop. 1:1. Only 5,216 shares taken up. Allotment of 5 equity shares pending. 1992 - Some of the new products introduded were Zidovir capsules an antiretroviral for HIV injection, Cipril tablets for hypertension, Optipres eyedrops for glaucoma patients, Felogard for hypertension, Nodine, a non-narcotic analgesic, etc. - In compliance with the provisions of the Companies Act, 1956, the Company redeemed its 6,000 preference shares of Rs 100 each as on 30th September. - Pref. shares redeemed on 30.9.92, 1,55,395 bonus equity shares issued in prop. 1:1. 1994 - New products introduced were - Beclate Aquanase - a major advancement in allergic rhinitis; Cytoplatin - an anticancer agent; Forcan - an antifungal; Imusporin - an immunosuppressant in organ transplantation; Kelfer - an iron chelator for thalassaemia; Lanzol - a proton pump inhibitor; Nuzac - an antidepresant; Odirox - a macrolide antibiotic and Qinarsol - for chloroquin-resistant malaria. - Equity shares subdivided 155,39,500. Equity shares allotted shares issued in prop. 1:5. - The Company's manufacturing unit at Kurkumbh, which was commissioned in April. The second phase of expansion of the location was under way and this was to provide specialised facilities for the manufacture of new chemical entites. 1995 - Effective 4th July, the Company was forced to declare a lock-out as some of the workmen at the Vikhroli Unit resorted to indiscipline. The Company initiated steps to mitigate the impact it could have on production. - New products introduced were - Acivir - antivirus herpes, Anlopres - antivirus herpes, Anlopres - Calcium channel blocker in hypertension and angina, Anlopres AT - a combination antihypertensive, Budecort 200 - a higher strength corticosterord in bronchial asthma, Budenase AQ - a corticosteroid protection in allergic rhinitis, cronal - a nast cell stabiliser in allerg ic conjunctivitis, cytonid - a antiandrogenic agent in prostate cancer, Norflox - an antidiarrhoeal in diarrhoea of mixed origin, optipes S - betaxocol eye drops, profenac - anti-inflammatory eye drops, Terfed D - a combination antihistamine and decongestant, Trivedon 20 - used in ischaemic heart disease. - A new chemical entity, candocuronium iodide - a neuromuscular blocking agent was manufactured, other new bulk drugs manufactured include: Acyelovir - antiviral, Amlodipine besylate - antihypertensive and antianginal, Febantel - veterinary anthelmintic, Flutamide - antiandrogen, Flutivcasone dipropionate - a corticosteriod, zenprolide acetate - GMRH analogue. - 13,43,383 rights equity shares issued (Prem. Rs. 60/-). However, the Rights issue was underwritten. 1996 - The products launched during the year were Azee (azithromycin capsules) - a new macrolide antibiotic; Budecort (budesonide rotacaps) - dry powder inhaled corticosteriod therapy for asthama; Cipril H (lisionopril + hydrochlorothiazide tablets) - a combination antihypertensive; Ciplox TZ (ciprofloxacin + tinidazole tablets) - the combination bactericide for aerobic/anaerobic infections; Entosec (secnidazole tablets) - single dose therapy for amoebiasis/trichomoniasis; Fincar (fin asterid tablets) - for beign prostatic hyperphasia; Metolar (metaprolol injection) - beta-blocker protection for post myocardial infarction & Zoflut (fluticasone propionate cream) - a new topical corticosteroid. 1997 - The products introduced during the year were; Alerid-D - an antihistamine and decongestant for cold and congestion, Amlopres L - a tablet for hypertension, Apuatears - an eye drop, Azee 1000 - a single dose for STDs, Budecort Respules - neubulised corticosteroid therapy for asthma, Dilgard XL - a diltiazem, Glumet - tablet for obese diabetics, Glygard - tablet for abese diabetics, Glygard - tablet for diabetics, Ipranase AQ (ipratropium nasal spray) - an anticholinergic therapy for rhinorrhoea, Ocutim (an eye drop) - a glaucoma therapy in acquafilm formulation, Osteifos 10 - tablet for osteoporosis, Prolyte Fizz - a rehydration effervescent tablet, Pylokit - an advanced H pylori kit, Risnia - an a typical antipsychotic, Stavir - an antiretroviral for AIDS, Synclar 250 - an advanced macrolide antibiotic, Theoday - a tablet for asthma, Zoflut Lotion - a topical corticosteroid. - The bulk division of the Company had taken up, the development and manufacture of some new drugs viz., budesonide - antiasthmatic corticosteroid, carvedilol - alpha/beta blocker, ebastine - antihistamine, formoterol fumarate - antiasthmatic, meloxicam - for osteroarthritis and rheumatoid arthritis, moclobemide - antidepressant, mometasome furoate - antiflammatory corticosteroid, pantorazole sodium sesquihydrate - antiulcerant, sildenafil citrate - erectile dysfuncion. - The Company has developed a form-fill-seal equipment for the first time in India, for the manufacture of sterile formulations. This was commissioned at Vikhroli factory and is working to its full capacity. Additional capacities were set up at Kurkumbh for manufacture of effervescent tablets, soft gel capsules and injectable formulations. The Company has incurred a capital expenditure of Rs 22.73 crores during the year. - The Rs. 3.69 billion Cipla has finalised a marketing joint venture with Australia-based Genpharm, as part of its strategy to consolidate its global presence. - Pharmaceutical major Cipla Ltd grabbed the attention of traders at the Mumbai Stock Exchange (BSE) on December 26 after a large block of about 75,000 shares of the company valued at little over Rs 5 crore changed hands. - The Rs.369-crore Cipla Ltd has entered into a souring arrangement with US-based Geneva Pharmaceuticals, a wholly-owned subsidiary of Swiss multinational Ciba, for a range of generic drugs. 1998 - Pharmaceutical companies, Cipla and Wockhardt, will be seeking shareholders' approval for a proposed share buyback at their forthcoming annual general meetings. - In a notice to shareholders, Cipla has proposed introduction of a new article, Article 64 A, in the Articles of Association of the company to enable the company to purchase and re-issue any of its shares. The existing Article 64 prohibits the company from buying its own shares and applying any of its funds for the purchase of any shares of the company. - The share price of Cipla Ltd, the leading pharmaceutical company scaled a new peak of Rs 920 on the Mumbai Stock Exchange on Sept 29 following fresh bull charge. The scrip opened at Rs 900 and shot up to Rs 920 during mid-session and closed at Rs 884 following hectic trading activities. 1999 - Ranbaxy and Cipla, have entered into a strategic partnership to jointly market a select basket of drugs. The alliance will bring forth their strengths in the strongly emerging cardiovascular and perennial anti-infectives market. - As a first step, the two molecules being jointly launched are Carvedilol, a new generation anti-hypertensive and Cefpodoxime Proxetil, an advanced third generation oral cephalosporin. - The Rs 541-crore Cipla has forged a strategic alliance with the UK-based Neolab for marketing a range of generic drugs. The alliance, while improving the Indian company's access to the multi-billion dollar European market for off-patent drugs, will also see Cipla rake in royalties on sales of products covered under the deal. - Cipla's latest tie-up in the international market comes close on the heels of the company's strategic partnership with the Delhi-based Ranbaxy Laboratories for a select basket of drugs. - The Mumbai-based Cipla is working on abbreviated new drug applications (ANDAs) in collaboration with international generics firms for a range of products like flutamide (for advanced prostatic cancer) and felodipine, for hypertension. 2000 - Cipla and Ranbaxy Laboratories have expanded an existing partnership by adding one more new drug in their co-marketing arrangement. 2001 - Cipla has tied up with the US-based Zenith Goldline and United Research Labs for marketing Flutamide, an oncology drug, and Felodipine, a cardiovascular drug, in the US and European markets. - Domestic pharma giant, Cipla, has despatched its first free consignment of anti-AIDS drug, `Nevirapine', to the Indian Government for distribution under the public health system. 2002 -Reduces the price of its anti-HIV medicines such as Stavir, Lamivir, Nevimune, Dinex, Indivan, Triomune, Efavir and Duovir -Revokes interim dividend of Rs 5 per share on face value of Rs 10 per share for FY 2001-02 -Company included in the World Health Organisation's (WHO's) list of HIV-related products -Chairman and Managing Director YK Hamied was presented with the lifetime contribution award for excellence in the pharmaceutical industry by Union chemicals & fertilisers minister SS Dhindsa -Resigns from Indian Pharmaceutical Alliance (IPA) over Patents Bill 2003 -Applies its requisiton for Abbreviated New Drug Application (ANDA) with US regulators for a post-menopausal drug -National Pharmaceutical Pricing Authority (NPPA) issues notices to Cipla along with Ranbaxy for overcharging the products -Completes research studies on three Anti-HIV Drugs -Registers Stavudine, Nevirapine, other anti-AIDS products in South Africa 2004 -Signs long-term agreement with Morton Grove Pharmaceuticals Inc (MGP) of Illinois, US, for product launch in the US market -Avesthagen forges alliance with Cipla -Cipla has joined a global initiative taken up by the Vatican in collaboration with global generic pharmaceutical manufacturers and the International Federation of Catholic Pharmacies and Academics to float CUMVIVIUM -Cipla join hands with Pentech Pharma -Indian pharma major Cipla, a pioneer in supplying cheap generic AIDS drugs in Africa, has patented its three-in-one combination tablet Triomune in South Africa -Cipla introduces 'Duova' to fight chronic obstructive pulmonary disease - Launches a new treatment for arthritis in technical collaboration with California-based Cymbiotics Inc. 2005 -Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. -Cipla introduces new drug for arthritis -Cipla to sign deal with Akorn Inc for anti-infective drug -Cipla to produce generic versin of bird-flu drug -Cipla to join hands with Roche - Cipla introduces new drug for arthritis 2006 - Cipla receives Scrip Award for Best Company in an Emerging Market -Safe & steady strategy gives Cipla lead over Ranbaxy -Cipla sets up subsidiary in Dubai -Cipla ties up with Ivax for US market -Cipla receives tentative US FDA approval for AIDS drugs -Cipla receives Pharma Excellence Award for 'Sustained Growth' -Cipla has given the Bonus in the Ratio of 3:2 2007 - Cipla unveils anti-malaria global initiative. -Set-up state-of-the-art facility for manufacture of formulations at Sikkim. -Award for the Forbes Asia's Best Under A Billion List! -Cipla's drug included in US anti-AIDS initiative -Anti-AIDS blitz sees pharma firms locked in ugly battle -Cipla launches emergency contraception tablet -Cipla launches estradiol transdermal spray in India -Cipla launches cut-price zanamivir in India -Cipla receives International Trade Awards 2006 for outstanding exporter of the year (Pharmaceuticals, Healthcare and Life Sciences category) 2008 -Cipla Ltd has appointed Mr. Pankaj Patel as a Director in casual vacancy with effect from March 05, 2008. -Cipla launched Roche's generic version of anti-infection drug 2009 -Cipla wins Erlotinib case against Roche -Pharmaceuticals Export Promotion Council Awards -Cipla launches drug to treat Swine flu virus -Cipla wins patent fight against Gilead Sciences 2010 -Cipla Ltd acquired Meditab Specialities Pvt. Ltd. ("Meditab") for an aggregate consideration of Rs. 133.35 crores. -Cipla Medpro has signed a deal with Biomab, a division of Chinese company Desano Pharma. -Cipla sold the marketing rights of i-Pill to Piramal Healthcare for Rs 95 crore in cash. -Cipla has tied up with the Manipal Group-promoted 'Stempeutics Research'. - Drug Maker Cipla has launched the generic Version of Pirfenidone, used to treat Idiopathic Pulmonary Fibrosis, a progressive Lung disease.India is the 2nd market to have this drug after Japan. 2011 -Cipla Cancer Palliative Care Centre launched 24 hour helpline to offer counselling to ensure more people use of the free services available. 2012 -Cipla India's second largest drug firm, has agreed to acquire South African Drugmaker Cipla Medpro with 51% stake amounts to $220 Million. -Cipla bags tentative approval for HIV treatment tablets -Drug giant Cipla Ltd has announced price reduction on 3 major anti-cancer drugs including Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). -Cipla bags award in the Field of Export of Pharmaceuticals during the year conferred the Highest Award 'Platinum'. 2013 -Cipla announces an offer to the shareholders of Medpro for 100% acquisition -Cipla launches the first Biosimilar of Etanercept in India 2014 -Cipla wins USD 188.95 million of Global Fund ARV Tender -MMV announces collaborations with Cipla and Strides -Cipla licenses rights for innovative product - Cipla, S&D Pharma collaborate to enter Czech Republic and Slovakia -Cipla collaborates with Hetero to launch its second biosimilar drug `Darbepoetin alfa' -Cipla invests in Chase Pharmaceuticals to support Alzheimer's disease drug development -The Registered Office of the Company has been shifted from Mumbai Central, Mumbai - 400008 to Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013, Tel: 022-24826000 / 022-2482695,1Fax: 022-24826893. 2015 -Cipla Ltd has entered into an agreement with partner, Biopharm SPA, to form a joint venture (JV) company in Algeria. -Cipla Ltd has launched the generic drug Sofosbuvir in brand name Hepcvir -Cipla Ltd has inked an agreement with Serum Institute of India Ltd. (SII) to market flu vaccine Nasovac-S. -Cipla Ltd has entered into a definitive agreement with Biopharma SPA for establishing a joint venture company in Algeria. -Cipla Ltd has launched a anti-ageing skin care product Cutisera&trade. developed by Stempeutics. -Cipla has launched generic tablets used for treating of hepatitis C under the brand name Hepcvir-L 2016 -Cipla gets CCI approval for investment by FIL Capital -Cipla completes acquisition of generic businesses in US -Cipla gets USFDA nod for generic anti-depressant drug -Cipla gets EIR from US FDA for Indore facility -Cipla gets USFDA final nod for Hepatitis B treatment drug -Cipla receives final approval for generic Baracluder tablets 2017 - Cipla Ltd "Authorised Key Managerial Personnel to determine materiality of events/information". - Cipla launches Hepatitis B vaccine in India - Cipla receives approval for Lamivudine Tablets - Cipla USA signs licensing agreement with MEDRx - Cipla gets WHO nod to sell TB preventing drug in HIV patients - Cipla launches Q-TIB globally - Cipla launches Rectal Artesunate Suppositories for severe malaria in young children - Cipla Receives Final Approval for Generic Epzicomr Tablets - Cipla launches Hepatitis B vaccine in India

Registered Office

Taza Block, Amba Tareythang Illaka, Rorathang,

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.